Nonengraftment Haploidentical Cellular Immunotherapy for Refractory Malignancies: Tumor Responses without Chimerism

Biology of Blood and Marrow Transplantation

Volumn 15, Issue 4, 2009, Pages 421-431

  Colvin, Gerald A ^a   Berz, David ^a   Ramanathan, Muthalagu ^b   Winer, Eric S ^a   Fast, Loren ^a   Elfenbein, Gerald J ^c   Quesenberry, Peter J ^a  

^a RHODE ISLAND HOSPITAL   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bone marrow transplantation; Haploidentical; Immunotherapy; Radiation

Indexed keywords

CD3 ANTIGEN; CYCLOSPORIN A; GRANULOCYTE COLONY STIMULATING FACTOR; HLA ANTIGEN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CANCER IMMUNOTHERAPY; CANCER RELAPSE; CELLULAR IMMUNITY; CHIMERA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS REACTION; DONOR LYMPHOCYTE INFUSION; ENGRAFTMENT; ENGRAFTMENT SYNDROME; FEMALE; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HAPLOIDY; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOMA; MALE; NONMYELOABLATIVE CONDITIONING; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; TREATMENT RESPONSE; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD3; BONE MARROW TRANSPLANTATION; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT VS HOST DISEASE; HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY; LYMPHOCYTE TRANSFUSION; MALE; MIDDLE AGED; NEOPLASMS; RECURRENCE; SURVIVAL RATE; TRANSPLANTATION CHIMERA; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; WHOLE-BODY IRRADIATION;

EID: 61749104445     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2008.12.503     Document Type: Article

References (50)

1. Coley W.B. The treatment of malignant tumors by repeated inoculations of erysipelas, with a report of ten original cases: 1893. Am J Med Sci 105 (1893) 487-511
2. Wiemann B., and Starnes C.O. Coley's toxins, tumor necrosis factor and cancer research: a historical perspective. Pharmacol Ther 64 (1994) 529-564
3. Kolb H., Mittermuller J., and Clemm C. Donor leukocyte transfusions for treatment of recurrent chronic myelogeneous leukemia in marrow transplant patients. Blood 76 (1990) 2462-2465
4. Bortin M.M., Rimm A.A., and Saltzstein E.C. Graft-versus-leukemia: quantification of adoptive immunotherapy in murine leukemia. Science 179 (1973) 811-813
5. Odom L., August C., and Githen J. Remission of relapsed leukemia during graft-versus-host reaction. Lancet 2 (1978) 537-540
6. Weiden P.L., Flourney N., Thomas E.D., et al. Anti-leukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow graft. New Engl J Med 300 (1979) 1068-1073
7. Bradley M.B., Sattler R.M., Raftopoulos H., et al. Correction of phenotype in a thalassemia mouse model using a nonmyeloablative marrow transplantation regimen. Biol Blood Marrow Transplant 8 (2002) 453-461
8. Quesenberry P.J., Stewart M.F., Peters S., et al. Engraftment of hematopoietic stem cells in nonmyeloablated and myeloablated hosts. Stem Cells 15 Suppl 1 (1997) 167-169
9. Nilsson S.K., Dooner M.S., Tiarks C.Y., et al. Potential and distribution of transplanted hematopoietic stem cells in a nonablated mouse model. Blood 89 (1997) 4013-4020
10. Quesenberry P.J., Ramshaw H., Crittenden R.B., et al. Engraftment of normal murine marrow into nonmyeloablated host mice. Blood Cells 20 (1994) 348-350
11. Ramshaw H.S., Crittenden R.B., Dooner M., et al. High levels of engraftment with a single infusion of bone marrow cells into normal unprepared mice. Biol Blood Marrow Transplant 1 (1995) 74-80
12. D'Hondt L., Lambert J.F., Damon J., et al. Engraftment of post-5-fluorouracil murine marrow into minimally myeloablated (100 cGy) murine hosts. J Hematother Stem Cell Res 11 (2002) 483-490
13. Stewart F.M., Crittenden R.B., Lowry P.A., et al. Long-term engraftment of normal and post-5-fluorouracil murine marrow into normal nonmyeloablated mice. Blood 81 (1993) 2566-2571
14. Stewart F.M., Zhong S., Wuu J., et al. Lymphohematopoietic engraftment in minimally myeloablated hosts. Blood 91 (1998) 3681-3687
15. Colvin G.A., Lambert J.F., Abedi M., et al. Murine marrow cellularity and the concept of stem cell competition: geographic and quantitative determinants in stem cell biology. Leukemia 18 (2004) 575-583
16. Ballen K.K., Becker P.S., Emmons R.B.V., et al. Low-dose total body irradiation followed by allogeneic lymphocyte infusion may induce remission in patients with refractory hematologic malignancy. Blood 100 (2002) 442-450
17. Sondel P.M., and Hank J.A. Alien-driven diversity and alien-selected escape: a rationale for allogeneic cancer immunotherapy. Transplant Proc 13 (1981) 1915-1921
18. Bortin M.M., Truitt R.L., Rimm A.A., et al. Graft-versus-leukemia activity induced by alloimmunization without augmentation of graft-versus-host activity. Nature 281 (1979) 490-491
19. Horowitz M.M., Gale R.P., Sondel P.M., et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75 (1990) 555-562
20. Pion S., Fontaine P., Baron C., et al. Immunodominant minor histocompatibility antigens expressed by mouse leukemic cells can serve as effective targets for T cell immunotherapy. J Clin Invest 95 (1995) 1561-1568
21. Tempelis L.D., Wasik M.R., and Bortin M.M. Adoptive immunotherapy of disseminated malignancies. Role of alien histocompatibility antigens on cancer cells and effectiveness of cells from alloimmunized donors. Ric Clin Lab 13 (1983) 163-182
22. Reisner Y., Kapoor N., Kirkpatrick D., et al. Transplantation for severe combined immunodeficiency with HLA-A, -B, -D, and -DR incompatible parental marrow cells fractionated by soybean agglutinin and sheep red blood cells. Blood 61 (1983) 341-348
23. Ferrara J., Lipton J., Hellman S., et al. Engraftment following T-cell-depleted marrow transplantation, I: the role of major and minor histocompatibility barriers. Transplantation 43 (1987) 461-467
24. Hong R., Horowitz S., Moen R., et al. Thymus and B cell reconstitution in severe combined immunodeficiency after transplantation of monoclonal antibody-depleted parental mismatched bone marrow. Bone Marrow Transplant 4 (1987) 405-409
25. Aversa F., Tabilio A., Velardi A., et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med 339 (1998) 1186-1193
26. Lacerda J.F., Martins C., Carmo J.A., et al. Haploidentical stem cell transplantation with purified CD34 cells after a chemotherapy-alone conditioning regimen. Biol Blood Marrow Transplant 9 (2003) 633-642
27. Aversa F., Terenzi A., Tabilio A., et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol 23 (2005) 3447-3454
28. Kanda Y., Oshima K., Asano-Mori Y., et al. In vivo alemtuzumab enables haploidentical human leukocyte antigen-mismatched hematopoietic stem cell transplantation without ex vivo graft manipulation. Transplantation 79 (2005) 1351-1357
29. Daly A., McAfee S., Dey B., et al. Nonmyeloablative bone marrow transplantation: infectious complications in 65 recipients of HLA-identical and mismatched transplants. Biol Blood Marrow Transplant 9 (2003) 373-382
30. Waller E.K., Giver C.R., Rosenthal H., et al. Facilitating T-cell immune reconstitution after haploidentical transplantation in adults. Blood Cells Mol Dis 33 (2004) 233-237
31. Pan L., Delmonte Jr. J., Jalonen C.K., et al. Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease. Blood 86 (1995) 4422-4429
32. Zeng D., Dejbakhsh-Jones S., and Strober S. Granulocyte colony-stimulating factor reduces the capacity of blood mononuclear cells to induce graft-versus-host disease: impact on blood progenitor cell transplantation. Blood 90 (1997) 453-463
33. Franzke A., Piao W., Lauber J., et al. G-CSF as immune regulator in T cells expressing the G-CSF receptor: implications for transplantation and autoimmune diseases. Blood 102 (2003) 734-739
34. Anasetti C., Amos D., Beatty P.G., et al. Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. New Engl J Med 320 (1989) 197-204
35. Sykes M., Romick M.L., and Sachs D.H. Interleukin 2 prevents graft-versus-host disease while preserving the graft-versus-leukemia effect of allogeneic T cells. Proc Natl Acad Sci U S A 87 (1990) 5633-5637
36. Mapara M.Y., Yong-Mi K., Sheng-Ping W., et al. Donor lymphocyte infusions mediate superior graft-versus-leukemia effects in mixed compared to fully allogeneic chimeras: a critical role for host antigen-presenting cells. Blood 100 (2002) 1903-1909
37. Spitzer T.R., McAfee S., Sackstein R., et al. The intentional induction of mixed chimerism and achievement of anti-tumor responses following non-myeloablative conditioning therapy and HLA-matched donor marrow transplantation for refractory hematologic malignancies. Biol Blood Marrow Transplant 6 (2000) 309-320
38. Dey B.R., McAfee S., Colby C., et al. Impact of prophylactic donor leukocyte infusions on mixed chimerism, graft-versus-host disease, and antitumor response in patients with advanced hematologic malignancies treated with nonmyeloablative conditioning and allogenieic bone marrow transplantation. Biol Blood Marrow Transplant 9 (2003) 320-329
39. Dey B.R., McAfee S., Colby C.D., et al. Anti-tumor response despite loss of donor chimaerism in patients treated with non-myeloablative conditioning and allogeneic stem cell transplantation. Br J Haematol 128 (2005) 351-359
40. Rajewsky K., Schirrmacher V., Nase S., et al. The requirement of more than one antigenic determinant for immunogenicity. J Exp Med 129 (1969) 1131-1143
41. Katz D.H., Ellman L., Paul W.E., et al. Resistance of guinea pigs to leukemia following transfer of immunocompetent allogeneic lymphoid cells. Cancer Res 32 (1972) 133-140
42. Ellman L., Katz D.H., Green I., et al. Mechanisms involved in the antileukemic effect of immunocompetent allogeneic lymphoid cell transfer. Cancer Res 32 (1972) 141-148
43. Symons H.J., Levy M.Y., Wang J., et al. The allogeneic effect revisited: exogenous help for endogenous, tumor-specific T cells. Biol Blood Marrow Transplant 14 (2008) 499-509
44. Rubio M.T., Kim Y.M., Sachs T., et al. Antitumor effect of donor marrow graft rejection induced by recipient leukocyte infusion in mixed chimeras prepared with nonmyeloablative conditioning: critical role for recipient-derived IFN-gamma. Blood 102 (2003) 2300-2307
45. + cells are responsible for the rapid elimination of allogeneic donor lymphoid cells. J Immunol 157 (1996) 4805-4810
46. Stauss H., Xue S., Gillmore R., et al. Exploiting alloreactivity for tumour immunotherapy. Vox Sang 87 Suppl 2 (2004) 227-229
47. Zarling J., Bach F., and Kung P. Sensitization of lymphocytes against pooled allogeneic cells, II: characterization of effector cells cytotoxic for autologous lymphoblastoid cell lines. J Immunol 126 (1981) 375-378
48. Zarling J., Kay N., Grant B., et al. Human anti-lymphoma responses generated in vitro and in vivo following sensitization by allogeneic leukocytes. Cancer Immunol Immunother 5 (1983) 237-239
49. + cells are effective alloantigen-presenting cells. Blood 96 (2000) 1144-1149
50. Lee T.H., Donegan E., Slichter S., et al. Transient increase in circulating donor leukocytes after allogeneic transfusions in immunocompetent recipients compatible with donor cell proliferation. Blood 85 (1995) 1207-1214